Mechanism and inhibition of saFabI, the enoyl reductase from Staphylococcus aureus

Biochemistry

Volumn 47, Issue 14, 2008, Pages 4228-4236

  Xu, Hua ^a   Sullivan, Todd J ^a,d   Sekiguchi, Jun Ichiro ^b   Kirikae, Teruo ^b   Ojima, Iwao ^a   Stratton, Christopher F ^a,e   Mao, Weimin ^c   Rock, Fernando L ^c   Alley, M R K ^c   Johnson, Francis ^a   Walker, Stephen G ^a   Tonge, Peter J ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c PFIZER INC   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG RESISTANT STRAINS; ENOYL REDUCTASE; KINETIC ASSAYS; STAPHYLOCOCCUS AUREUS;

DRUG DOSAGE; ENZYME INHIBITION; ETHERS; FATTY ACIDS; MUTAGENESIS;

BACTERIA;

5 CHLORO 2 PHENOXYPHENOL; 5 ETHYL 2 PHENOXYPHENOL; ACYL CARRIER PROTEIN; ACYL COENZYME A DEHYDROGENASE (NADP); BACTERIAL ENZYME; FATTY ACID; PHENOL DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRICLOSAN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM MUTANT; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; STAPHYLOCOCCUS AUREUS; WILD TYPE;

AMINO ACID SEQUENCE; CATALYSIS; CONSERVED SEQUENCE; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENZYME ACTIVATION; ENZYME INHIBITORS; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MUTATION; PHENYL ETHERS; SEQUENCE ALIGNMENT; STAPHYLOCOCCUS AUREUS; SUBSTRATE SPECIFICITY;

STAPHYLOCOCCUS AUREUS;

EID: 41849144862     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi800023a     Document Type: Article

References (44)

1. Diekema, D. J., Pfaller, M. A., Schmitz, F. J., Smayevsky, J., Bell, J., Jones, R. N., and Beach, M. (2001) Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32 (Suppl. 2), S114-S132.
2. Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Kugler, K. C., and Beach, M. L. (1999) Survey of blood stream infections attributable to Gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Diagn. Microbiol. Infect. Dis. 33, 283-297.
3. Peacock, S. J., de Silva, I., and Lowy, F. D. (2001) What determines nasal carriage of Staphylococcus aureus? Trends Microbiol. 9, 605-610.
4. Bradley, S. F. (1992) Methicillin-resistant Staphylococcus aureus infection. Clin. Geriatr. Med. 8, 853-868.
5. Barber, M. (1961) Methicillin-resistant staphylococci. J. Clin. Pathol. 14, 385-393.
6. Panlilio, A. L., Culver, D. H., Gaynes, R. P., Banerjee, S., Henderson, T. S., Tolson, J. S., and Martone, W. J. (1992) Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect. Control Hosp. Epidemiol. 13, 582-586.
7. Gaynes, R., and Culver, D. (1997)Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) in the United States, 1975-1996. National Nosocomial Infection Surveillance (NNIS) System. Annual Meeting of the Infectious Disease Society of America (IDSA), San Francisco.
8. From the Centers for Disease Control and Prevention (2002) Vancomycin resistant Staphylococcus aureus - Pennsylvania, 2002, in Journal of the American Medical Association, p 2116.
9. Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T., and Tenover, F. C. (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40, 135-136.
10. Egan, A. F., and Russell, R. R. (1973) Conditional mutations affecting the cell envelope of Escherichia coli K-12. Genet. Res. 21, 139-152.
11. Turnowsky, F., Fuchs, K., Jeschek, C., and Hogenauer, G. (1989) envM genes of Salmonella typhimurium and Escherichia coli. J. Bacteriol. 171, 6555-6565.
12. Heath, R. J., and Rock, C. O. (1995) Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. J. Biol. Chem. 270, 26538-26542.
13. Rawat, R., Whitty, A., and Tonge, P. J. (2003) The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance. Proc. Natl. Acad. Sci. U.S.A. 100, 13881-13886.
14. Baldock, C., Rafferty, J. B., Sedelnikova, S. E., Baker, P. J., Stuitje, A. R., Slabas, A. R., Hawkes, T. R., and Rice, D. W. (1996) A mechanism of drug action revealed by structural studies of enoyl reductase. Science 274, 2107-2110.
15. Karlowsky, J. A., Laing, N. M., Baudry, T., Kaplan, N., Vaughan, D., Hoban, D. J., and Zhanel, G. G. (2007) In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. 51, 1580-1581.
16. Kitagawa, H., Kumura, K., Takahata, S., Iida, M., and Atsumi, K. (2007) 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI. Bioorg. Med. Chem. 15, 1106-1116.
17. Ling, L. L., Xian, J., Ali, S., Geng, B., Fan, J., Mills, D. M., Arvanites, A. C., Orgueira, H., Ashwell, M. A., Carmel, G., Xiang, Y., and Moir, D. T. (2004) Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase. Antimicrob. Agents Chemother. 48, 1541-1547.
18. Payne, D. J., Miller, W. H., Berry, V., Brosky, J., Burgess, W. J., Chen, E., DeWolf, W. E., Jr., Fosberry, A. P., Greenwood, R., Head, M. S., Heerding, D. A., Janson, C. A., Jaworski, D. D., Keller, P. M., Manley, P. J., Moore, T. D., Newlander, K. A., Pearson, S., Polizzi, B. J., Qiu, X., Rittenhouse, S. F., Slater-Radosti, C., Salyers, K. L., Seefeld, M. A., Smyth, M. G., Takata, D. T., Uzinskas, I. N., Vaidya, K., Wallis, N. G., Winram, S. B., Yuan, C. C., and Huffman, W. F. (2002) Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. 46, 3118-3124.
19. Zhang, Y. M., and Rock, C. O. (2004) Evaluation of epigallocatechin gallate and related plant polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid synthase. J. Biol. Chem. 279, 30994-31001.
20. Heath, R. J., Li, J., Roland, G. E., and Rock, C. O. (2000) Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J. Biol. Chem. 275, 4654-4659.
21. Slater-Radosti, C., Van Aller, G., Greenwood, R., Nicholas, R., Keller, P. M., DeWolf, W. E., Jr., Fan, F., Payne, D. J., and Jaworski, D. D. (2001) Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus. J. Antimicrob. Chemother. 48, 1-6.
22. Russell, A. D. (2004) Whither triclosan? J. Antimicrob. Chemother. 53, 693-695.
23. Regos, J., Zak, O., Solf, R., Vischer, W. A., and Weirich, E. G. (1979) Antimicrobial spectrum of triclosan, a broad-spectrum antimicrobial agent for topical application. II. Comparison with some other antimicrobial agents. Dermatologica 158, 72-79.
24. Ayliffe, G. A., Buckles, A., Casewell, M. W., Cookson, B. D., Cox, R. A., Duckworth, G. J., Griffiths-Jones, A., Heathcock, R., Humphreys, H., Keane, C. T., Marples, R. R., Shanson, D. C., Slack, R., and Tebbs, E. (1998) Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. British Society for Antimicrobial Chemotherapy, Hospital Infection Society and the Infection Control Nurses Association. J. Hosp. Infect. 39, 253-290.
25. Bamber, A. I., and Neal, T. J. (1999) An assessment of triclosan susceptibility in methicillin-resistant and methicillin-sensitive Staphylococcus aureus. J. Hosp. Infect. 41, 107-109.
26. Fan, F., Yan, K., Wallis, N. G., Reed, S., Moore, T. D., Rittenhouse, S. F., DeWolf, W. E., Jr., Huang, J., McDevitt, D., Miller, W. H., Seefeld, M. A., Newlander, K. A., Jakas, D. R., Head, M. S., and Payne, D. J. (2002) Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 46, 3343-3347.
27. Seaman, P. F., Ochs, D., and Day, M. J. (2007) Small-colony variants: A novel mechanism for triclosan resistance in methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 59, 43-50.
28. Sivaraman, S., Sullivan, T. J., Johnson, F., Novichenok, P., Cui, G., Simmerling, C., and Tonge, P. J. (2004) Inhibition of the bacterial enoyl reductase FabI by triclosan: A structure-reactivity analysis of FabI inhibition by triclosan analogues. J. Med. Chem. 47, 509-518.
29. Sullivan, T. J., Truglio, J. J., Boyne, M. E., Novichenok, P., Zhang, X., Stratum, C. F., Li, H. J., Kaur, T., Amin, A., Johnson, F., Slayden, R. A., Kisker, C., and Tonge, P. J. (2006) High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem. Biol. 1, 43-53.
30. Parikh, S., Moynihan, D. P., Xiao, G., and Tonge, P. J. (1999) Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis. Biochemistry 38, 13623-13634.
31. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
32. Quadri, L. E., Weinreb, P. H., Lei, M., Nakano, M. M., Zuber, P., and Walsh, C. T. (1998) Characterization of Sfp, a Bacillus subtilis phosphopantetheinyl transferase for peptidyl carrier protein domains in peptide synthetases. Biochemistry 37, 1585-1595.
33. Cleland, W. W. (1979) Statistical analysis of enzyme kinetic data. Methods Enzymol. 63, 103-138.
34. CLSI (2006) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 6th ed., Approved Standard M7-A6, Clinical and Laboratory Standards Institute, Wayne, PA.
35. Schaeffer, M. L., Agnihotri, G., Kallender, H., Brennan, P. J., and Lonsdale, J. T. (2001) Expression, purification, and characterization of the Mycobacterium tuberculosis acyl carrier protein, AcpM. Biochim. Biophys. Acta 1532, 67-78.
36. Bergler, H., Wallner, P., Ebeling, A., Leitinger, B., Fuchsbichler, S., Aschauer, H., Kollenz, G., Hogenauer, G., and Turnowsky, F. (1994) Protein EnvM is the NADH-dependent enoyl-ACP reductase (FabI) of Escherichia coli. J. Biol. Chem. 269, 5493-5496.
37. Heath, R. J., Su, N., Murphy, C. K., and Rock, C. O. (2000) The enoyl-[acyl-carrier-protein] reductases FabI and FabL from Bacillus subtilis. J. Biol. Chem. 275, 40128-40133.
38. Marcinkeviciene, J., Jiang, W., Kopcho, L. M., Locke, G., Luo, Y., and Copeland, R. A. (2001) Enoyl-ACP reductase (FabI) of Haemophilus influenzae: Steady-state kinetic mechanism and inhibition by triclosan and hexachlorophene. Arch. Biochem. Biophys. 390, 101-108.
39. Heath, R. J., Rubin, J. R., Holland, D. R., Zhang, E., Snow, M. E., and Rock, C. O. (1999) Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem. 274, 11110-11114.
40. Heath, R. J., Yu, Y. T., Shapiro, M. A., Olson, E., and Rock, C. O. (1998) Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 273, 30316-30320.
41. McMurry, L. M., Oethinger, M., and Levy, S. B. (1998) Triclosan targets lipid synthesis. Nature 394, 531-532.
42. Levy, C. W., Roujeinikova, A., Sedelnikova, S., Baker, P. J., Stuitje, A. R., Slabas, A. R., Rice, D. W., and Rafferty, J. B. (1999) Molecular basis of triclosan activity. Nature 398, 383-384.
43. Heath, R. J., and Rock, C. O. (2000) A triclosan-resistant bacterial enzyme. Nature 406, 145-146.
44. Delano, W. L. (2002) The PyMOL Molecular Graphics System, DeLano Scientific LLC, San Carlos, CA.